[Feedback from two French addiction centers and national survey on the intranasal naloxone (Nalscue
Retour d’expérience de deux CSAPA et enquête nationale sur la naloxone intranasale (Nalscue
Administration, Intranasal
Adult
Aged
Ambulatory Care Facilities
/ statistics & numerical data
Drug Overdose
/ mortality
Female
France
/ epidemiology
Health Knowledge, Attitudes, Practice
Humans
Male
Middle Aged
Naloxone
/ administration & dosage
Narcotic Antagonists
/ therapeutic use
Opioid-Related Disorders
/ drug therapy
Surveys and Questionnaires
Young Adult
Addictologie
Addictology
Naloxone
Opiacés
Opiates
Opioids
Opioïdes
Overdose
Risk reduction
Réduction des risques
Journal
Therapie
ISSN: 1958-5578
Titre abrégé: Therapie
Pays: France
ID NLM: 0420544
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
24
09
2018
revised:
18
12
2018
accepted:
17
01
2019
pubmed:
23
2
2019
medline:
6
2
2020
entrez:
23
2
2019
Statut:
ppublish
Résumé
France has temporarily authorized addictology centers to use a form of intranasal naloxone (Nalscue Patient data are those requested under Nalscue Over this period, in the two addiction centers, 370 kits (35% of the national total) were distributed to 330 patients including 312 opioid users. Of these users, 15% report injecting and 85% are poly-consumers. In 14% of the cases, a patient's relative was formed to administrate the Nalscue The interest of intranasal naloxone is no longer to be demonstrated in a context of opioid overdose, but the preauthorized framework did not allow a major diffusion of the antidote within the population most at risk. Let us hope that the availability in pharmacy can promote its distribution and thus reduce the number of deaths.
Identifiants
pubmed: 30792078
pii: S0040-5957(19)30009-5
doi: 10.1016/j.therap.2019.01.005
pii:
doi:
Substances chimiques
Narcotic Antagonists
0
Naloxone
36B82AMQ7N
Types de publication
Journal Article
Multicenter Study
Langues
fre
Sous-ensembles de citation
IM
Pagination
477-486Informations de copyright
Copyright © 2019 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.